Share

Dr. Emad Shash discusses organizational and regulatory constraints for international clinical trials for rare cancers

In an article appearing in ecancermedicalscience, the EORTC’s Emad Shash, Anastassia Negrouk, Sandrine Marreaud, Vassilis Golfinopoulos, Denis Lacombe and Francoise Meunier outline organizational and regulatory constraints for international clinical trials for rare cancers. In an accompanying interview, Dr. Shash offers further insight into this topic.

Back to news list

Related News

  • Professor Benjamin Besse becomes President of EORTC

  • CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

  • EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials

  • New study confirms a key quality of life tool can be used with adolescents with cancer

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

  • Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

  • EORTC’s presence at ESTRO 2026

  • Interview of ROSC Chair, Joost Vaerhoeff